A groundbreaking new Nature study reveals that cancer cells use specialized genomic “retention elements” to preserve and propagate extrachromosomal circular DNA (ecDNA)—a major engine of oncogene amplification and tumor evolution. These circular ecDNAs, which lack centromeres and segregate randomly, should theoretically be lost at each cell division. Yet this work shows that cancer cells have evolved a mechanism to tether ecDNA to mitotic chromosomes, ensuring their inheritance and continued oncogenic drive.
The authors identify thousands of CpG-rich retention sequences, often hypomethylated, that interact with mitotic “bookmarking” proteins to hitchhike ecDNA into daughter cells. Hypomethylation is crucial—when these CpG sites were experimentally methylated, ecDNA failed to tether properly and was lost. This establishes a powerful epigenetic axis: hypomethylation enables ecDNA persistence; methylation disrupts retention and reduces tumor viability.
Another major insight: these molecules are circular, megabase-scale structures that frequently incorporate multiple retention elements. Circular DNA is highly susceptible to topological strain, supercoiling, and the enzymatic actions of DNA topoisomerases, which modulate DNA winding and relieve torsional stress. The presence of circular oncogenic ecDNA therefore strongly suggests that Top1 and Top2 enzymes are functionally engaged in their replication, segregation, and maintenance. Targeting these enzymes—already validated anticancer strategies—may be even more impactful when extrachromosomal circular DNA biology is considered.
Why this Matters for Cancer Therapeutics and for TopoGEN Users
If ecDNA is a primary engine of oncogenesis, and if its circular structure depends on topoisomerase activity, then topo-based therapeutics (Top1 and Top2 poisons, catalytic inhibitors, and combination therapies) may help destabilize the very structures that maintain oncogenic amplification.
TopoGEN’s specialized ICE Assays, Enzyme Kits, Repair Pathway Reporters, and Topo-Targeted Drug Discovery Platforms are uniquely suited for studying how drugs interact with ecDNA maintenance pathways—empowering researchers to develop the next generation of therapies that suppress ecDNA retention, amplify DNA damage, and block tumor evolution.